Are you validating your packaging process?

A company recently received this 483 observation:

….. Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product..

 Specifically, there is no documentation of the packaging process for … being validated to provide a high degree of assurance that the filling and packaging operations are consistently meeting the drug product attributes.

For more observations pertaining to packaging and labeling, see Issue 1045 available today.  It also has observations pertaining to lab controls, manufacturing controls, and medical devices.

Stay in Compliance! Subscribe today!

Become A Subscriber And Stay Ahead of the FDA

To get the most out of GMP Trends®, sign up to one of our subscription packages for valuable, up-to-date information you won't find anywhere else! Every subscription provides the most frequently cited FDA 483 observations taken from recent FDA Inspections. The non-essential information is redacted to streamline the facts in an easily readable format. Join the thousands of professionals who rely on GMP Trends® to keep them informed of the latest FDA Enforcement Trends!

SUBSCRIBE NOW